These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 10717525)

  • 1. p53-regulated GML gene expression in non-small cell lung cancer. a promising relationship to cisplatin chemosensitivity.
    Higashiyama M; Miyoshi Y; Kodama K; Yokouchi H; Takami K; Nishijima M; Nakayama T; Kobayashi H; Minamigawa K; Nakamura Y
    Eur J Cancer; 2000 Mar; 36(4):489-95. PubMed ID: 10717525
    [TBL] [Abstract][Full Text] [Related]  

  • 2. GPI-anchored molecule-like protein (GML) expression in non-small cell lung cancer (NSCLC).
    Komiya T; Hirashima T; Kikui M; Fukuoka M; Ohno A; Kawase I
    Anticancer Res; 1999; 19(5B):4315-9. PubMed ID: 10628393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunohistochemical p53 protein status in nonsmall cell lung cancer is a promising indicator in determining in vitro chemosensitivity to some anticancer drugs.
    Higashiyama M; Kodama K; Yokouchi H; Takami K; Doi O; Kobayashi H; Tanisaka K; Minamigawa K
    J Surg Oncol; 1998 May; 68(1):19-24. PubMed ID: 9610658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [The importance of p53 and ras mutation as predictive markers for adjuvant chemotherapy in non-small-cell lung cancer].
    Hirai Y; Shimizu Y; Oura S; Yoshimasu T; Ota F; Nakamura R; Naito K; Nishiguchi H; Hashimoto S; Okamura Y
    Gan To Kagaku Ryoho; 2012 Mar; 39(3):381-4. PubMed ID: 22421763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.
    Guntur VP; Waldrep JC; Guo JJ; Selting K; Dhand R
    Anticancer Res; 2010 Sep; 30(9):3557-64. PubMed ID: 20944137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The potential clinical value of GML and the p53 gene as a predictor of chemosensitivity for colorectal cancer.
    Hashimoto Y; Ueda K; Minami K; Watatani M
    Int J Clin Oncol; 2001 Apr; 6(2):90-6. PubMed ID: 11706756
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
    Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
    Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The modifier subunit of glutamate cysteine ligase relates to cisplatin resistance in human small cell lung cancer xenografts in vivo.
    Nishi M; Abe Y; Fujimori S; Hamamoto A; Inoue Y; Miyazaki N; Oida Y; Ikoma N; Ohnishi Y; Yamazaki H; Ueyama Y; Nakamura M
    Oncol Rep; 2005 Aug; 14(2):421-4. PubMed ID: 16012725
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Knockdown of Merm1/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels.
    Yan D; Zheng X; Tu L; Jia J; Li Q; Cheng L; Wang X
    Mol Med Rep; 2015 Jan; 11(1):295-302. PubMed ID: 25352209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. p53 gene status modulates the chemosensitivity of non-small cell lung cancer cells.
    Lai SL; Perng RP; Hwang J
    J Biomed Sci; 2000; 7(1):64-70. PubMed ID: 10644891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
    Gao J; Meng Q; Zhao Y; Chen X; Cai L
    BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Downregulated long non-coding RNA TRPM2-AS inhibits cisplatin resistance of non-small cell lung cancer cells via activation of p53- p66shc pathway.
    Ma LY; Xie XW; Ma L; Pang JL; Xiong XM; Zheng HD; Shen XL; Wen ZG; Wang HY
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2626-2634. PubMed ID: 28678322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Downregulation of Meg3 enhances cisplatin resistance of lung cancer cells through activation of the WNT/β-catenin signaling pathway.
    Xia Y; He Z; Liu B; Wang P; Chen Y
    Mol Med Rep; 2015 Sep; 12(3):4530-4537. PubMed ID: 26059239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
    Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
    Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
    [TBL] [Abstract][Full Text] [Related]  

  • 15. TMEM158 and FBLP1 as novel marker genes of cisplatin sensitivity in non-small cell lung cancer cells.
    Mohammed Ael S; Eguchi H; Wada S; Koyama N; Shimizu M; Otani K; Ohtaki M; Tanimoto K; Hiyama K; Gaber MS; Nishiyama M
    Exp Lung Res; 2012 Nov; 38(9-10):463-74. PubMed ID: 23098063
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
    Wang HJ; Yang ZX; Dai XT; Chen YF; Yang HP; Zhou XD
    Apoptosis; 2017 Sep; 22(9):1157-1168. PubMed ID: 28677094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-202 Enhances the Anti-Tumor Effect of Cisplatin on Non-Small Cell Lung Cancer by Targeting the Ras/MAPK Pathway.
    Sun W; Ping W; Tian Y; Zou W; Liu J; Zu Y
    Cell Physiol Biochem; 2018; 51(5):2160-2171. PubMed ID: 30522099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
    Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
    PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restoration of wild-type p53 activity enhances the sensitivity of pleural metastasis to cisplatin through an apoptotic mechanism.
    Riva CM
    Anticancer Res; 2000; 20(6B):4463-71. PubMed ID: 11205289
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness.
    Pavan S; Olivero M; Corà D; Di Renzo MF
    Eur J Cancer; 2013 Mar; 49(4):964-73. PubMed ID: 23079474
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.